Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$1.64
+0.6%
$1.78
$1.32
$2.72
$238.04M1.71158,131 shs73,418 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$0.76
$0.81
$0.66
$2.28
$29.66M1.57164,989 shs153,839 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$0.87
-11.1%
$0.82
$0.25
$8.90
$2.76M1.155,799 shs427 shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$5.26
-0.6%
$4.79
$2.10
$6.07
$827.27M0.662.06 million shs2.06 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
+0.61%-2.96%-4.09%+6.49%-19.21%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.00%+9.35%-3.18%-15.96%-65.92%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-11.12%-2.25%+22.54%+17.57%-85.43%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-0.57%-1.50%+19.55%+27.98%+104.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
1.501 of 5 stars
3.51.00.00.03.30.00.0
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
1.0695 of 5 stars
0.03.00.00.03.80.80.6
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.8235 of 5 stars
0.05.00.00.00.62.50.0
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
3.9536 of 5 stars
2.43.00.04.23.32.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.00
Buy$7.00326.83% Upside
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.00
N/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00
N/AN/AN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
2.83
Moderate Buy$6.2518.82% Upside

Current Analyst Ratings Breakdown

Latest IMMP, XERS, SCYX, and VCNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$6.00 ➝ $7.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$5.14M46.60N/AN/A$1.05 per share1.56
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$3.75M7.91N/AN/A$1.45 per share0.52
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$388K5.83N/AN/A($2.59) per share-0.34
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$203.07M4.05N/AN/A($0.20) per share-26.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$21.29M-$0.56N/A15.20N/A-1,030.04%-53.47%-32.86%8/6/2025 (Estimated)
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$20.25M-$48.27N/AN/AN/AN/A-383.58%8/12/2025 (Estimated)
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$54.84M-$0.30N/AN/AN/A-20.25%N/A-12.07%8/6/2025 (Estimated)

Latest IMMP, XERS, SCYX, and VCNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million
5/8/2025Q1 2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$0.07-$0.06+$0.01-$0.06$57.61 million$57.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
18.86
N/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
5.83
5.83
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/A
0.77
0.77
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/A
1.72
1.17

Institutional Ownership

CompanyInstitutional Ownership
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
50.11%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
42.75%

Insider Ownership

CompanyInsider Ownership
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.86%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
51.50%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
6.47%
CompanyEmployeesShares OutstandingFree FloatOptionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021146.04 million141.56 millionOptionable
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
6039.02 million37.12 millionOptionable
Vaccinex, Inc. stock logo
VCNX
Vaccinex
402.60 million1.26 millionNo Data
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
290156.38 million146.27 millionOptionable

Recent News About These Companies

Xeris Biopharma Holdings, Inc. (XERS) - Yahoo Finance
Xeris Announces Details for Analyst & Investor Day

New MarketBeat Followers Over Time

Media Sentiment Over Time

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$1.64 +0.01 (+0.61%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$1.66 +0.03 (+1.52%)
As of 06:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$0.76 0.00 (0.00%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$0.76 +0.00 (+0.39%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Vaccinex stock logo

Vaccinex NASDAQ:VCNX

$0.87 -0.11 (-11.12%)
As of 07/16/2025 01:47 PM Eastern

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Xeris Biopharma stock logo

Xeris Biopharma NASDAQ:XERS

$5.26 -0.03 (-0.57%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$5.38 +0.12 (+2.19%)
As of 07:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.